author-photo

Hermini Manzano

16

Papers

143

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Prospective Biomarker Study in Advanced RAS Wild‐Type Colorectal Cancer: POSIBA Trial (GEMCAD 10‐02)

2019 Oncologist
Show All
- Source
- Cite
- Save
Citations (5)
Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti–Epidermal Growth Factor Receptor Therapy

2019
Show All
- Source
- Cite
- Save
Citations (3)
Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients

2018 Neoplasia
Show All
- Source
- Cite
- Save
Citations (7)
Prospective evaluation of BRAF, PI3K and PTEN as predictive and prognostic biomarkers in first-line advanced KRAS wild-type colorectal cancer treated with FOLFOX or FOLFIRI plus bi-weekly cetuximab. GEMCAD 10-02

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
PULSE, a phase 2 study of mFOLFOX6-panitumumab (P) with biomarker stratification as first-line chemotherapy (CT), in patients (pts) with KRAS (exon 2) metastatic colorectal cancer (mCRC). A GEMCAD 09-03 study

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Diagnosis delay and follow-up strategies in colorectal cancer. Prognosis implications: a study protocol

2010 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (5)
Phase i trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma

2005 International Journal of Radiation Oncology Biology Physics
Show All
- Source
- Cite
- Save
Citations (9)
Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according to toxicity prognostic factors.

2004 Anti-Cancer Drugs
Show All
- Source
- Cite
- Save
Citations (5)
A phase I study of radiation therapy (RT) with concurrent oxaliplatin (OXL), cisplatin (P) and protacted infusion 5-fluorouracil (FU) for locally advanced esophageal (ES) or gastroesophageal (GEJ) carcinoma

2004 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)